is ro going to stop selling semaglutide NEW RESEARCH SHOWS HELPS PATIENTS ACHIEVE WEIGHT LOSS AND SAFETY OUTCOMES CONSISTENT WITH CLINICAL TRIALS Novo Nordisk partners with Ro,
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
population classified as clinically obese, the potential for significant growth is clear
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC
Dufour JF, Caussy C, Loomba R
Certain patients, including those with a history of medullary thyroid carcinoma, should not use these medications
Theres no information about dose-dependent effects (whether 2.4mg semaglutide means more risk than 1mg)
